Background: Little research exists to demonstrate efficacy and verification measures of the Baha â system versus traditional bone-conduction hearing aids. This study gives statistical data about 10 children who have used traditional bone-conduction hearing aids, Baha coupled to a Softband, and the Baha system implanted.
P reviously amplification technologies for atresia and microtia have been limited to conventional bone-conduction devices with wire headbands for infants and children. More recently, the Baha â system offers an alternative for these cases. Some research exists that compares the Baha with conventional boneconduction hearing aids and shows improved functional gain in the high frequencies and better speech recognition; however, those studies use a traditional metal headband that can be at times uncomfortable to patients and difficult to fit on small children. (Browning and Gatehouse, 1994; Hakansson, Carlsson, Tjellstron, Liden, 1994; van der Pouw et al, 1999) .
The Baha system is a surgically implantable amplification option to consider for children with bilateral congenital conductive and/or mixed hearing loss. It was first introduced in 1977 (Tjellstrom and Hakansson, 1995) , and then received approval by the Food and Drug Administration (FDA) for use with conductive and mixed hearing loss in 1999 (FDA, 1999) , for pediatric patients older than five years of age and adults. The FDA approved it for bilateral implantation in 2001 (FDA, 2001 ) and for use with unilateral or single-sided deafness for persons five years of age and older in 2002 (FDA, 2002) .
The implantable Baha system consists of external and internal components. The sound processor and abutment are the external components of the system, and the titanium implant is the internal component. The titanium implant and the abutment when connected are referred to as the fixture. The sound processor connects via the abutment when the Baha system is implanted in the skull bone behind the ear. This surgical procedure provides an alternative pathway for sound via direct bone conduction without the use of headbands.
The Baha Softband (Fig. 1) is utilized for infants and young children who do not fit into the surgical category due to current FDA age requirements, offering a solution for children awaiting surgery and/or for older children as a trial prior to surgery. The Baha Softband is comprised of an elastic band with a Velcro fastener, with the sound processor connected via a plastic disk.
In 2005, Snik et al published consensus statements on the Baha System. Snik et al reported on the performance of the Baha system versus conventional bone-conduction devices in children and adults (Powell et al, 1996; Lustig et al, 2001; Tietze and Papsin, 2001; Snik et al, 2004) . The results of transcutaneous application of the Baha system were found comparable to those of conventional bone-conduction devices (Hol et al, 2005) . Snik et al also concluded that better gain and output can be obtained with percutaneous transmission of sound versus transcutaneous (Hakansson et al, 1985; Tjellstrom et al, 2001) . Hol et al (2005) assessed audibility performance with the Baha Softband. Their study investigated two children with bilateral congenital aural atresia fit with the Baha Compact coupled to a Softband. Hol et al found that while the overall difference in functional gain between the Baha Compact on a Softband and the Oticon E 300P was similar, there was more functional gain in the low and midfrequencies as compared to the conventional bone-conduction device (Oticon E 300P). Despite the small sample size, the Hol et al study demonstrated that the results of Baha use with a Softband are at least comparable if not a little more favorable than conventional bone-conduction devices. Verstraeten et al (2009) studied the comparison of the audiologic results between three conditions: the Baha implanted unilaterally, the Baha coupled to a headband (Fig. 2) , and the Baha coupled to the test band (Fig. 3) . Their studies revealed significant differences in the audiometric thresholds and the speech understanding scores in the preoperative test conditions and in the final postoperative conditions. Also studied was the difference between the Baha headband versus the Baha test band. The test band is a tighter fitting metal headband that gives more acute audiological testing prior to implantation; however, the test band gives most patients significant discomfort after about two hours. The results in Verstraeten et al's study of the two headbands revealed that these two headbands are comparable and the regular headband should be given to patients to avoid the discomfort of the test band. Their results indicate that for frequencies 1 to 4 kHz, significant differences were found between the Baha coupled to the abutment and the preoperative testing conditions versus either of the headbands. This difference for 1 to 4 kHz was in the range of 5 to 20 dB. Significant differences were also noted in speech reception thresholds by approximately 4 to 7 dB.
Past clinical experiences with the Baha Softband at Arkansas Children's Hospital have proven more comfortable and an easier-to-wear alternative for infants and toddlers. Because of the sizing and elastic component of the Baha Softband, it can be fit as soon as the hearing loss has been diagnosed, reducing the auditory deprivation.
Because bone-conduction devices are unable to be verified electroacoustically in a clinical situation, there is less attention in the literature to this dilemma. Children born with atresia and microtia are unable to wear air-conduction hearing aids, which are more easily verified clinically. The Pediatric Amplification Protocol published in 2003 by the American Academy of Audiology (Academy) recommended aided sound-field thresholds as a "verification" procedure for bone-conduction devices. This measure is the most appropriate fitting verification for Baha and/or other bone-conduction devices as traditional real ear measures with boneconduction devices are not a clinically viable alternative at this time. Because of the Academy's protocol, functional gain was the verification method chosen for this study and is used consistently with other measures in the Audiology Clinic at Arkansas Children's Hospital for Baha verification for bilateral conductive and mixed hearing loss. The purpose of this study was to compare functional gain at 500, 1000, 2000, and 4000 Hz for infants and children with bilateral conductive hearing loss who were initially fit with traditional bone-conduction devices then progressed to Baha with Softband and finally to unilateral Baha implants. 
Participants
Ten participants met the following inclusion criteria: (1) 6 mo to 18 yr of age, (2) congenital bilateral conductive hearing loss, (3) initially fit with a traditional boneconduction hearing aid, (4) fit unilaterally with a Baha Compact or Divino via the Softband, (5) implanted unilaterally with the Baha system, (6) unaided and aided soundfield thresholds available for four frequencies from 500 to 4000 Hz, and (7) consistent full-time use of amplification. Participants ranged in age from 6 mo to 16 yr of age; three were male and seven were female. Two participants were African-American, five Caucasian, and three Hispanic.
Procedures
Medical records of participants with bilateral conductive hearing loss fit with amplification at Arkansas Children's Hospital were reviewed. From the audiograms in the medical records, ear-and frequency-specific thresholds obtained via supra-aural headphones at 500, 1000, 2000, and 4000 Hz were recorded on data sheets and transferred to an Excel spreadsheet. Audiometric data for frequency-specific unaided and aided sound-field thresholds obtained with the speaker positioned at a 90 o azimuth to the target ear were likewise recorded and transferred to the Excel spreadsheet at corresponding frequencies. The ear-specific data were averaged for statistical analysis.
Statistical Analysis
Single-factor, repeated analyses of variance (ANOVAs; repeated on frequency) were run to examine the amount of functional gain delivered by the various devices as well as the threshold measures with each device at each frequency. The general model employed for these ANOVAs was E(Y) 5 amplification device 1 error (1).
Also of interest was the effect of frequency on each individual device for both functional gain and threshold measures. Similar to above, single-factor repeated ANOVAs (repeated on device) were used to look at differences across frequency in functional gain and threshold using the following model: E(Y) 5 frequency 1 error (2).
RESULTS

T
he current study was undertaken to examine whether functional gain and threshold measures varied among the frequencies of 500, 1000, 2000, and 4000 Hz when measured with the following devices: bone-conduction transducer, traditional boneconduction hearing aid, bone-anchored implant (Baha) attached to a Softband headband and an implanted Baha. Functional gain was calculated by subtracting the threshold measured with a device in place from the sound-field threshold measured for that individual with no device in place. An a priori p-value of 0.05 was chosen for significance on all statistical tests.
Functional Gain
The mean functional gain values in dB are graphed as a function of frequency in Figure 4 , with the standard error indicated for each measure. The open circles represent functional gain for the bone-conduction transducer, the open diamonds for a traditional boneconduction hearing aid, open squares for the Baha device attached to a Softband, and the open triangle the Baha device implanted. There are several interesting points to note about these data. First, as expected, a bone-conduction transducer provides the most gain of any device tested, followed closely by the implanted Baha, the Baha on a Softband, and finally, with much less gain, a traditional bone-conduction hearing aid. Second, among these 16 measures of functional gain there is minimal overlap among devices at 1000 Hz, but at no other frequency. We undertook a series of ANOVAs to compare the functional gain of these four devices at each frequency. Asterisks can be seen above the open circle markers at each frequency, indicating overall significant differences of p , 0.001 in each case. Because the ANOVAs indicated at least one difference at each frequency, post hoc pairwise comparisons with Bonferroni correction were run to determine where those differences were. Table  1 contains the mean differences as well as asterisks to indicate the significant differences. In Table 1 , positive values indicate more functional gain for the device at the top of each column compared to the device listed at the left of each row, while negative values indicate the device at left yielded higher gain than the device at the column head. We use asterisks to denote the p-value for each statistical difference, with one asterisk representing p # 0.05, two asterisks p # 0.01, and three asterisks p # 0.001 Results of interest include: (1) an implanted Baha has statistically as much gain as a bone-conduction transducer at all frequencies tested; (2) an implanted Baha provides statistically more gain at 500 Hz than the Baha attached to a Softband; and (3) a traditional bone-conduction hearing aid provides significantly less gain than all the other devices at all frequencies with the exception of the Baha with Softband at 2000 Hz. We suspect this comparison was not significant due to the small number of subjects. Even in that comparison, however, the Baha on a Softband yields 6.7 dB more mean gain than the bone-conduction hearing aid, an amount that is clinically significant.
In a second series of ANOVAs each device was assessed across frequency. A number sign to the right of each set of markers in Figure 4 indicates significance across frequency for that device at p , 0.02 or less. Results of the analyses are delineated in Table 2 . Although each ANOVA did reveal an overall effect, the post hoc analyses show that only the bone-conduction transducer had a significant difference in functional gain between 500 and 2000 Hz and the traditional bone-conduction hearing aid a difference between 500 and 4000 Hz. Measures of functional gain with the Baha, both on the Softband and implanted, had no significant differences across frequency.
Threshold
Also of interest was examining the children's threshold measures across device and frequency. An analysis similar to that for functional gain was used, that is, a series of ANOVAs followed by Bonferroni-corrected post hoc analyses, as indicated. It is easily seen in Figure 5 that the unaided thresholds are much poorer, and significantly so, than any of the thresholds with an amplification device in place. One striking finding is that a traditional bone-conduction hearing aid yields thresholds at each frequency that are 10-15 dB poorer than the Baha device and 15-20 dB poorer than a bone-conduction transducer. Although a small difference, the implanted Baha does yield slightly better thresholds than the Baha on a Softband, and the transducer supplies slightly better thresholds than the Baha. The ANOVAs revealed at least one difference (in addition to the unaided thresholds) between some pair of devices at each frequency, as indicated by the asterisks below the open diamonds/traditional bone-conduction aid thresholds. The p-values were less than 0.02 at each frequency. Table 3 displays the mean differences among all pairs of devices as well as the significance, if any. As expected, unaided thresholds are significantly poorer than all others at all frequencies with p , 0.001 in each case. The post hoc analyses also show that thresholds measured with a traditional bone-conduction hearing aid are significantly poorer than the bone-conduction transducer and the Baha, whether the Baha is attached to a Softband or is implanted at 500, 1000, and 4000 Hz. At 2000 Hz, the bone-conduction aid exhibits its most Hz, but with a mean threshold difference of 6 dB is not statistically similar to the bone-conduction transducer at 500 Hz. The Softband Baha has thresholds 6-14 dB poorer (higher) than the bone-conduction transducer, values that are clinically significant, yet statistical significance was reached at only 500 and 4000 Hz. A final comparison between the two Baha devices indicates no statistical differences between these measures. The implanted Baha has a poorer mean threshold (4.4 dB) at 500 Hz than the Softband Baha; however, the implanted Baha provides better (lower) thresholds at 1000, 2000, and 4000, and further, that difference increases as frequency increases. We also examined the thresholds across frequency for each device; mean differences can be seen in Table  4 . There were few significant findings in these analyses. The ANOVAs for the implanted Baha and the bone-conduction transducer indicated no differences across frequency. The ANOVA run for the boneconduction hearing aid was significant (p 5 0.048), but no significance was found for any pair in the post hoc analysis. The Softband Baha was significant in the ANOVA and did yield three differences among frequencies in its post hoc analysis: 1000 Hz had better thresholds than either 500 or 4000 Hz, and the threshold at 2000 Hz was better than that at 4000 Hz. Finally, the unaided threshold at 2000 Hz was significantly better than that at 500 Hz, a notunexpected result given the transmission characteristics of the ear. Snik et al (2005) that support the use of the Baha system as a viable treatment for permanent congenital and acquired conductive hearing loss for infants and children. Furthermore, the results are consistent with the results of Verstraeten et al (2009) , which found significant differences between the Baha coupled to the abutment and the preoperative testing conditions of either the testband or the headband.
Participants in this study showed a statistically significant improvement when using the Baha Softband over traditional bone-conduction hearing aids. An implanted Baha had statistically as much gain as a bone-conduction transducer at all frequencies tested.
These results demonstrate the benefit of the Baha system, either on a Softband or implanted. Based on these results the Baha system should be used as a first choice in intervention rather than a last option for inoperable conductive hearing loss. We feel strongly that the results of this study provide data necessary to demonstrate support for third-party reimbursement for the bone-anchored implants.
